Skip to main content
. Author manuscript; available in PMC: 2017 Dec 26.
Published in final edited form as: Oncogene. 2017 Jun 26;36(43):5939–5947. doi: 10.1038/onc.2017.197

Figure 3. Effects of MKP-1 deletion and MAPK inhibition on cisplatin sensitivity and PARP-1 and PAR expression.

Figure 3

(A) MTT analyses of cell viability in MKP-1+/+ and MKP-1−/− MEF cells after treatment with 2 μg/mL cisplatin with or without 10 μM U012 6 (U), 10 μM SB203580 (SB) or 10 μM SP600125 (SP) for 48 hr. (B) Immunoblot analyses of PARP-1 and PAR levels in MEF cells treated as in (A) for 24 hr. (C) Immunoblot analyses of the amounts of the indicated proteins in MKP-1+/+ and MKP-1−/− MEF cells after treatment with 2 μg/mL cisplatin with or without 10 μM SP600125 (SP) for 24 hr. (D) Immunoblot analyses of PARP-1, PAR and JNK1/2 levels in JNK1/2+/+ MEFs and JNK1/2−/− MEFs exposed to 2 μg/mL cisplatin for 24 hr.